Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Raw Materials (2019 - 2025)

Historic Raw Materials for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q1 2025 value amounting to $435799.0.

  • China SXT Pharmaceuticals' Raw Materials rose 3588.06% to $435799.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $435799.0, marking a year-over-year increase of 3588.06%. This contributed to the annual value of $435799.0 for FY2025, which is 3588.06% up from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Raw Materials of $435799.0 as of Q1 2025, which was up 3588.06% from $320722.0 recorded in Q1 2024.
  • In the past 5 years, China SXT Pharmaceuticals' Raw Materials registered a high of $435799.0 during Q1 2025, and its lowest value of $243222.0 during Q1 2023.
  • For the 3-year period, China SXT Pharmaceuticals' Raw Materials averaged around $333247.7, with its median value being $320722.0 (2024).
  • Its Raw Materials has fluctuated over the past 5 years, first skyrocketed by 3186.39% in 2024, then surged by 3588.06% in 2025.
  • China SXT Pharmaceuticals' Raw Materials (Quarter) stood at $243222.0 in 2023, then skyrocketed by 31.86% to $320722.0 in 2024, then surged by 35.88% to $435799.0 in 2025.
  • Its last three reported values are $435799.0 in Q1 2025, $320722.0 for Q1 2024, and $243222.0 during Q1 2023.